While assisting an intricate clinical approval process within the next 2 to 3 years for any group of new cancer drugs, Genentech must create a lengthy-term capacity arrange for a significant type of new cancer items. Contributing to the complexness and uncertainty is always that charge here we are at planning, building, and validating a brand new $600 million plus production-scale facility is 5 years. Additionally, making certain the best process technologies are integrated into this type of new plant helps make the task facing David Ebersman, the senior vice-leader of items procedures, and the management team a challenging one. Frames the problems Ebersman and the team face and outlines the approach up to now.
Estimated Submission On |